Clinical Practice Pearls and the Future of SCLC
The panel shares clinical pearls for community oncologists treating small cell lung cancer.
Investigational Agents in SCLC in the Second Line Setting and Beyond
Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.
Choosing the Appropriate Treatment in the Second Line Setting in SCLC
Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.
Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting
Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.
Lurbinectedin for SCLC Treatment in the Second-Line Setting
Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.
Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy
The panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.
Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy
Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.
Ongoing Trials and Real-World Studies in Frontline SCLC
Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.
IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy
Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.
Management of Adverse Events Associated with Durvalumab + Chemotherapy
Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.
Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy
Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.
Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases
Charu Aggarwal, MD, MPH, presents the profile of a patient with small cell lung cancer with brain metastases to spark a discussion on treatment approaches in the frontline setting.
Progress in the Treatment and Management of SCLC
The panel discusses how the field of small cell lung cancer treatment has changed in recent years.
Use of the TNM Staging System in SCLC
Charles Rudin, MD, PhD, explains the prognostic staging systems used for small cell lung cancer.
Overview of SCLC and Importance of Early Diagnosis
Drs Owonikoko and Weiss provide a brief overview of small cell lung cancer and the vital importance of an early diagnosis to improve patient outcomes.
Dr. Owonikoko on the Efficacy of Selpercatinib in Pre-Treated and Untreated RET+ Thyroid Cancer
Taofeek Owonikoko MD, PhD, MSCR, discusses the efficacy of selpercatinib in pre-treated and treatment-naive patients with RET fusion–positive medullary thyroid cancer.
Dr. Owonikoko on Standard of Care for SCLC
Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.
Real-world Data Confirm Safety Profile for Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer
Frontline Adagrasib Plus Pembrolizumab Elicits Encouraging Clinical Activity in KRAS G12C+ Advanced NSCLC
Frontline Dostarlimab Shows Superior PFS vs Pembrolizumab in NSCLC
Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.